A Novel Needleless Liquid Jet injection Methodology for Improving Direct Cardiac Gene Delivery: An Optimization of Parameters, Aav Mediated Therapy and investigation of Host Responses in Ischemic Heart Failure
Date of Award
Doctor of Philosophy (PhD)
Charles R. Bridges
Heart disease remains the leading cause of mortality and morbidity worldwide, with 22 million new patients diagnosed annually. Essentially, all present therapies have significant cost burden to the healthcare system, yet fail to increase survival rates. One key employed strategy is the genetic reprogramming of cells to increase contractility via gene therapy, which has advanced to Phase IIb Clinical Trials for advanced heart failure patients. It has been argued that the most significant barrier preventing FDA approval are resolving problems with safe, efficient myocardial delivery, whereby direct injection in the infarct and remote tissue areas is not clinically feasible. Here, we aim to: (1) Improve direct cardiac gene delivery through the development of a novel liquid jet device approach (2) Compare the new method against traditional IM injection with two different vector constructions and evaluate outcome (3) Evaluate the host response resulting from both modes of direct cardiac injection, then advance a drug/gene combination with controlled release nanoparticle formulations.
Fargnoli, Anthony Samuel, "A Novel Needleless Liquid Jet injection Methodology for Improving Direct Cardiac Gene Delivery: An Optimization of Parameters, Aav Mediated Therapy and investigation of Host Responses in Ischemic Heart Failure" (2014). Publicly Accessible Penn Dissertations. 1273.